Xenova Group plc is losing a partner for its DNA-targeting oncology program.The Slough, UK-based company said Millennium Pharmaceuticals Inc. would no longer fund the program after the end of ongoing Phase I studies of XR11576 and XR5944, a decision made following an internal portfolio prioritization review. Millennium has been Xenova's North American partner for the program for three years. (BioWorld Today)

Xenova Group plc is losing a partner for its DNA-targeting oncology program.The Slough, UK-based company said Millennium Pharmaceuticals Inc. would no longer fund the program after the end of ongoing Phase I studies of XR11576 and XR5944, a decision made following an internal portfolio prioritization review. Millennium has been Xenova's North American partner for the program for three years. (BioWorld Today)